Aclidinium bromide/formoterol fumarate vs Glycopyrrolate/formoterol fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide/formoterol fumarate · Duaklir Pressair
Rights held by Azurity Pharmaceuticals and partners; US product discontinued
NCT01437397 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).
Reported efficacy
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)
Result source: NCT03022097
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide/formoterol fumarate | Glycopyrrolate/formoterol fumarate |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | 0.1 vs -0.0+0.1 vs placeboNCT014373975 other results
| —Not reported |
| SGRQ total, change | -6.6 vs -2.2−4.4 vs placeboNCT014373974 other results
| —Not reported |
| TDI focal score | 2.0 vs 0.6+1.4 vs placeboNCT014373975 other results
| —Not reported |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide/formoterol fumarate
- —Not reported
- Glycopyrrolate/formoterol fumarate
- —Not reported
Trough FEV1, change
- Aclidinium bromide/formoterol fumarate
- 0.1 vs -0.0+0.1 vs placeboNCT01437397
5 other results
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- Glycopyrrolate/formoterol fumarate
- —Not reported
SGRQ total, change
- Aclidinium bromide/formoterol fumarate
- -6.6 vs -2.2−4.4 vs placeboNCT01437397
4 other results
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- -8.7 vs -4.7 NCT03022097
- Glycopyrrolate/formoterol fumarate
- —Not reported
TDI focal score
- Aclidinium bromide/formoterol fumarate
- 2.0 vs 0.6+1.4 vs placeboNCT01437397
5 other results
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- 2.9 vs 2.1 NCT03022097
- 1.9 vs 1.9 NCT01908140
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aclidinium bromide/formoterol fumarate: 4 of 4 rows · Glycopyrrolate/formoterol fumarate: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide/formoterol fumarate | Glycopyrrolate/formoterol fumarate |
|---|---|---|
| Dropout rate | 19.5%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results18.3%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 14.1% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 10.5%400/6 μg NCT01462942 · Phase 3 32.4%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 0%b NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 6.2%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results6.5%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 4.7% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 2.6%400/6 μg NCT01462942 · Phase 3 6.6%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | —b NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 5.7%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results5.4%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 7.5% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 4.7%400/6 μg NCT01462942 · Phase 3 9.7%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 0%b NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 400/12 μga chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 15% headache 6% nasopharyngitis 5.6% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 400 μg/12 μg chronic obstructive pulmonary disease 27% urinary tract infection 6.6% nasopharyngitis 6.4% NCT01437540 · Phase 3 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide/formoterol fumarate
show 4 more results
show 5 more results
show 5 more results
show 4 more results
show 1 more result
Glycopyrrolate/formoterol fumarate
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Glycopyrrolate/formoterol fumarate's landscape